Clinical trials: Nutritional Evaluation
Type 2 Diabetes Mellitus
A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes
This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of different doses of…
- Trial name
- NCT07112872
- Testing
- RO7795081, Semaglutide
- Where
- 46 sites in United States, Hungary and 2 more
- Volunteers
- 330 people
- Sponsor
- Hoffmann-La Roche
Dyslipidemias, Cardiovascular Diseases
A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic
Atherogenic dyslipidemia includes patients who have coronary heart disease (CHD) or CHD risk equivalents, whose TG level is not adequately controlled after statin monotherapy.
- Conditions
- Dyslipidemias, Cardiovascular Diseases, Hypertriglyceridemia
- Trial name
- NCT01462877
- Testing
- fenofibrate
- Where
- China
- Volunteers
- 506 people
- Sponsor
- Abbott
Hyperlipidemia
Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C
Study to evaluate the pharmacokinetics and pharmacodynamics of inclisiran treatment given as single subcutaneous injection in Chinese participants with elevated low-density lipoprotein cholesterol (LDL-C) despite treatment with…
- Trial name
- ORION-14 (NCT04774003)
- Testing
- 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran), 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension and Dyslipidemia
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-348
- Trial name
- CKD-348 (NCT04660370)
- Testing
- CKD-348, CKD-828, D097, D337
- Where
- South Korea
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Obesity and Overweight
A Study to Evaluate a Postbiotic in Supporting Weight Loss and Metabolic Health
This study aims to evaluate the impact of a specific oral postbiotic supplement on metabolic health in overweight adults.
- Trial name
- NCT06911073
- Testing
- Postbiotic
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- ResBiotic Nutrition, Inc.
Diabetes Mellitus, Type 2, Obesity
A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight
Novo Nordisk is developing a new study medicine NNC0519-0130 to improve the treatment options for people living with type 2 diabetes and excess body weight.
- Trial name
- NCT07004322
- Testing
- NNC0519-0130
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Novo Nordisk A/S
Bone Loss
The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation
The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.
- Trial name
- LACE (NCT00674453)
- Testing
- Lasofoxifene
- Where
- United Kingdom
- Volunteers
- 51 people
- Sponsor
- Ligand Pharmaceuticals
Diabetes Mellitus, Type 1
Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2
DEFEND-2 is a Phase 3 confirmatory study for the Phase 3 DEFEND-1 study. The study objective is to find out if an 8-day series of otelixizumab infusions leads to greater improvement in insulin secretion as compared with placebo.
- Trial name
- DEFEND-2 (NCT01123083)
- Testing
- Otelixizumab
- Where
- Italy
- Volunteers
- 179 people
- Sponsor
- GlaxoSmithKline
Hypercholesterolemia
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
The purpose of this study is to determine whether ezetimibe/atorvastatin 10 mg/40 mg combination tablet is equivalent to the coadministration of ezetimibe 10 mg and atorvastatin 40 mg in lowering…
- Trial name
- NCT01370603
- Testing
- Atorvastatin, Ezetimibe, Ezetimibe/atorvastatin
- Volunteers
- 328 people
- Sponsor
- Organon and Co
Type 2 Diabetes Mellitus
Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)
The objective of this study is to evaluate the efficacy and safety of gemigliptin 50 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- NCT02831361
- Testing
- Gemigliptin, Metformin, Diet/exercise questionnaire
- Volunteers
- 290 people
- Sponsor
- LG Life Sciences
T2DM (Type 2 Diabetes Mellitus)
Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin
A Multi-center, Open-label, Extension study to Evaluate the long term Safety and Efficacy of DWP16001 add-on to metformin in Patients with type 2 diabetes mellitus inadequately controlled on metformin
- Trial name
- ENHANCE-MEXT (NCT05376969)
- Testing
- DWP16001
- Where
- South Korea
- Volunteers
- 159 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Overweight, Obesity
A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity
The study is being conducted to evaluate the efficacy and safety of HRS-7535 in subjects with overweight or obesity.
- Trial name
- NCT06904105
- Testing
- HRS-7535 Tablets
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2)
Long Term Extension Study in Patients With Primary Hyperoxaluria
The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of…
- Conditions
- Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases
- Trial name
- PHYOX3 (NCT04042402)
- Testing
- DCR-PHXC
- Where
- 23 sites in United States, Australia and 11 more
- Volunteers
- 75 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Pre-surgical Anxiety, Blood Glucose Concentration
Vis Pre Surgery Medical Food Validation Study
A pre-market, confirmatory, prospective, interventional, clinical investigation to confirm the clinical safety and performance profile of Vis Pre-surgeryTM that the medical food will reduce pre and post-surgical complications…
- Conditions
- Pre-surgical Anxiety, Blood Glucose Concentration, Blood Cortisol Levels, Electrolyte Levels
- Trial name
- NCT07359222
- Testing
- Pre-surgical medical food
- Where
- India
- Volunteers
- 67 people
- Sponsor
- TM Nutrition LLC
Postmenopausal Osteoporosis
A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.
This 2 arm study will investigate the efficacy and safety of Bonviva (150mg po monthly) in the prevention of glucocorticoid-induced osteoporosis in post-menopausal women.
- Trial name
- NCT00545051
- Testing
- ibandronate
- Where
- 15 sites in Finland
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)
This study is to characterize the pharmacokinetics, safety, tolerability, and pharmacodynamics of single and multiple oral doses (SD, MD) of ertugliflozin (PF-04971729, MK-8835) in Japanese healthy participants.
- Trial name
- NCT01223339
- Testing
- Ertugliflozin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice
This is an observational study in which data from people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who have already started or will start CKD or T2D treatment are collected and studied.
- Trial name
- FINEGUST (NCT05526157)
- Testing
- Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
- Where
- 5 sites in United States, Denmark and 3 more
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Urea Cycle Disorders
Clinical Food Study to Evaluate the Effect of KB195 on Gut Nitrogen Metabolism in Patients With Urea Cycle Disorders
This clinical food study aims to explore the effect of KB195, a novel mixture of oligosaccharides, on the metabolism of nitrogen by the microbiome in patients with urea cycle disorders (UCDs).
- Trial name
- NCT03797131
- Testing
- KB195 (a novel mixture of oligosaccharides)
- Where
- Switzerland
- Volunteers
- 4 people
- Sponsor
- Kaleido Biosciences
Type 2 Diabetes Mellitus
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
The purpose of this study is to investigate the effect of bexagliflozin compared to sitagliptin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03115112
- Testing
- Bexagliflozin, Sitagliptin
- Where
- 56 sites in United States, Czechia and 4 more
- Volunteers
- 386 people
- Sponsor
- Theracos
Obesity
Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066
The purpose of this study was to determine if LIK066 taken with a meal containing low carbohydrate is associated with less diarrhea compared to a high carbohydrate meal and to assess the potential effects of supplements such as…
- Trial name
- NCT03198767
- Testing
- LIK066, Carbohydrate 50%, Carbohydrate 25%
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.